Abcellera Biologics Inc ABCL

$11.62 -0.33 (-2.76%)

Valuation

Market cap
3,903,085,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,154,900
Avg volume
4,311,480
Day's range
$11.24 – $12.01
Shares out
326,618,000
Stochastic %K
39%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stockingtrade Nov 13, 2:37 AM
$ABCL When was the last time an insider sold this stock?
1 replies
cfdpaul Nov 12, 11:40 PM
$TNXP $ABCL This is what quality CEO does. BUY on the open market 13 times . https://www.google.com/search?ie=UTF-8&client=ms-android-uscellular-us-rvc3&source=android-browser&q=how+many+times+has+carl+hansen+bought+abcl+on+the+open+market+including+today
0 replies
Optionking1995 Nov 12, 11:36 PM
$VKTX $ABCL Abcellera CEO purchases 750k worth of shares on open market. Something Brian Lian, the greediest CEO in all of Biotech , would NEVER EVER do.
0 replies
erpy Nov 12, 11:23 PM
$ABCL This is what quality CEO's do. BUY on the open market 13 times . https://www.google.com/search?ie=UTF-8&client=ms-android-uscellular-us-rvc3&source=android-browser&q=how+many+times+has+carl+hansen+bought+abcl+on+the+open+market+including+today
0 replies
Ckkung71 Nov 12, 10:21 PM
$ABCL CEO Hansen buy and the shorters answer to sell quite same amount directly. They really work hard 🤔
0 replies
JennyRowes Nov 12, 10:06 PM
$ABCL does anyone have a record of how many times Hansen has bought on the open market?
1 replies
flymetothemoon2 Nov 12, 8:49 PM
$ABCL ❤️
0 replies
flymetothemoon2 Nov 12, 8:34 PM
$ABCL ABCELLERA 🔥 🔥 !!! 🤑😁👏🙌🏻
0 replies